Upcoming Events › Grant
Events Search and Views Navigation
Sponsor: American Society for Cell and Gene Therapy
Application Due Date: August 1, 2019
Awards and Eligibility: ASGCT will award a $50,000 Career Development Award to support independent transformative pilot studies in gene and cell therapy by ASGCT members, particularly those ideas that would be challenging to fund with normal funding mechanisms.
Molecular Mechanisms of Blood-Brain Barrier Function and Dysfunction in Alzheimer’s disease and Alzheimer’s related dementias (AD/ADRD) (R01 Clinical Trial Not Allowed)
LOI Due Date: September 9, 2019
Application Deadline: October 9, 2019
Description:The goal of this initiative is to elucidate the mechanistic links between blood brain barrier (BBB) dysfunction, Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD), and how related comorbidities impact the basic molecular mechanisms of BBB health and function.
Award: Application budgets are limited to $499,000 direct costs/year and need to reflect the actual needs of the proposed project.
LOI DUE OCTOBER 11, 2019
Drug Discovery Program
The Drug Discovery RFP supports novel drug programs and repurposed/repositioned programs. One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Program to Accelerate Clinical Trials (PACT)
The goal of this RFP is to increase the number of innovative pharmacologic interventions tested in clinical studies for Alzheimer’s disease and related dementias. The average award is up to $5 million based on stage and scope of research. Depending on the availability of funds, in certain cases, well-justified larger budgets may be considered.
This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use One year with potential for follow-on funding; average award is $150,000-$600,000 based on stage and scope of research.
Prevention Beyond the Pipeline
The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Awards range between $50,000-$100,000 for epidemiological analyses based on scope of research, and can reach up to $3 million for clinical trials based on stage and scope of research.
Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed)
Sponsor: NIH Common Fund Program
LOI Due Date: September 28, 2019
Application Deadline: October 28, 2019
Details: The goal of this funding opportunity announcement (FOA) for the Common Fund Program “Illuminating the Druggable Genome” (IDG; https://commonfund.nih.gov/idg/index) is to solicit applications for pilot projects on IDG-eligible understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) in order to study them beyond what the IDG’s Centers can accomplish and to validate and demonstrate the utility of IDG-generated reagents, data, and approaches.
Award: Application budgets are limited to $100,000 in direct costs (excluding subcontract F&A) for one year and need to reflect the actual needs of the proposed project.
Sponsor: National Institutes of Health
Due Date: November 5, 2019 by 5 pm local time of applicant
Award: Money, property, or both to carry out an approved project or activity. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. The maximum grant period is five years.
PROPOSALS ACCEPTED ON A ROLLING BASIS
Supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities.
Supports scientific conferences that are relevant to our mission with grants up to $10,000.
Sponsor: Physicans’ Services Incorporated Foundation
Due Date: Applications accepted on a rolling basis
Award: Grants up to $20,000 are available to cover the costs of the data gathering and analysis,
support staff and preparation of reports. Up to an additional $500 will be provided for travel
costs incurred in presenting papers on the results of a community practice study.
Find out more »